Adial Pharmaceuticals ADIL

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.00 (+0.00%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Adial Pharmaceuticals (ADIL)
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $0.7499

  • Market Cap

    $4.86 Million

  • Price-Earnings Ratio

    -0.28

  • Total Outstanding Shares

    6.58 Million Shares

  • Total Employees

    7

  • Dividend

    No dividend

  • IPO Date

    July 27, 2018

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    1180 seminole trail, Charlottesville, VA, 22901

  • Homepage

    https://www.adialpharma.com

Historical Stock Splits

If you bought 25 shares of ADIL before August 7, 2023, you'd have 1 share today.
Execution DateSplit Amount
August 7, 20231-for-25 (Reverse Split)

Cash Flow Statement

January 1, 2024 to December 31, 2024
MetricValue
Net Cash Flow From Financing Activities, Continuing$7.85 Million
Net Cash Flow From Operating Activities$-6.92 Million
Net Cash Flow, Continuing$0
Net Cash Flow From Investing Activities, Continuing$-923,443
Net Cash Flow From Financing Activities$7.85 Million
Net Cash Flow From Operating Activities, Continuing$-6.92 Million

Income Statement

January 1, 2024 to December 31, 2024
MetricValue
Preferred Stock Dividends And Other Adjustments$0
Net Income/Loss$-13.20 Million
Research and Development$3.23 Million
Operating Income/Loss$-8.28 Million
Net Income/Loss Attributable To Noncontrolling Interest$0
Operating Expenses$8.28 Million

Comprehensive Income

January 1, 2024 to December 31, 2024
MetricValue
Comprehensive Income/Loss$-13.20 Million
Comprehensive Income/Loss Attributable To Parent$-13.20 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Other Comprehensive Income/Loss$0

Balance Sheet

January 1, 2024 to December 31, 2024
MetricValue
Liabilities And Equity$5.04 Million
Equity$4.07 Million
Noncurrent Assets$985,178
Other Current Liabilities$725,728
Noncurrent Liabilities$0
Liabilities$975,858

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ADIL from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.